Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score - PubMed (original) (raw)

Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score

Jeong-Hyeon Kim et al. J Korean Med Sci. 2015 Mar.

Abstract

This study was conducted to assess the association between sarcopenic obesity and cardiovascular disease (CVD) risk in Korean adults (n=3,320; ≥40 yr) who participated in the 5th Korean National Health and Nutrition Examination Survey in 2010. The appendicular skeletal muscle mass divided by body weight was calculated for each participant; participants with values <1 standard deviation below the mean reference value (i.e., aged 20-39 yr) were considered sarcopenic. Subjects were further classified into 4 groups according to their obesity (i.e., body mass index ≥25 kg/m(2)) and sarcopenic status. Individuals' 10-yr CVD risk was determined using the Framingham risk model. The sarcopenic obese group had more participants (43.8% men, 14.6% women) with a high risk of CVD (≥20%). The sarcopenic obese group was associated with an increased 10-yr CVD risk than the non-sarcopenic, non-obese group (odds ratio [OR], 2.49; 95% confidence interval [CI], 1.53-4.06, P<0.001 in men; OR, 1.87; 95% CI, 1.02-3.41, P=0.041 in women). Sarcopenic non-obese and non-sarcopenic obese subjects were not associated with an increased 10-yr CVD risk. Sarcopenic obesity, but not non-sarcopenic obesity, was closely associated with an increased CVD risk in Korean adults.

Keywords: Cardiovascular Diseases; KNHANES; Obesity; Risk Assessment; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Fig. 1

Fig. 1

Framingham risk score category within sarcopenic obesity phenotype groups according to body mass index and sarcopenic status by sex (P < 0.001 across groups). Groups A (non-sarcopenic, non-obese), B (sarcopenic, non-obese), C (non-sarcopenic, obese), and D (sarcopenic, obese) are shown.

References

    1. Grimby G, Saltin B. The ageing muscle. Clin Physiol. 1983;3:209–218. - PubMed
    1. Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med. 2011;27:337–339. - PubMed
    1. Kim JH, Choi SH, Lim S, Yoon JW, Kang SM, Kim KW, Lim JY, Cho NH, Jang HC. Sarcopenia and obesity: gender-different relationship with functional limitation in older persons. J Korean Med Sci. 2013;28:1041–1047. - PMC - PubMed
    1. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS One. 2010;5:e10805. - PMC - PubMed
    1. Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, Kim KW, Lim JY, Park KS, Jang HC. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA) Diabetes Care. 2010;33:1652–1654. - PMC - PubMed

MeSH terms

LinkOut - more resources